# Peptide Compounding: The HHS Policy Explained for Operators

> Peptide compounding under the new HHS policy: the six peptides, the 10 conditions, what operators can and cannot do, and how to comment by November 13, 2026.

Source: https://www.fusehealth.com/blogs/peptide-compounding-hhs-policy-explained

---
[Insights](https://www.fusehealth.com/blogs)/Peptide Compounding Under the New HHS Policy: What Healthcare Operators Can and Cannot Do

BlogCompliance & LegalPeptidesRegulatoryOperator Guide

FUSE Health · 13 min read · November 6, 2026

# Peptide Compounding Under the New HHS Policy: What Healthcare Operators Can and Cannot Do

![Peptide Compounding Under the New HHS Policy - FUSE](https://cdn.sanity.io/images/yd6yvgd6/production/26d303dd5e2fe9cacc190866b09eb6c658bab4b1-1920x1080.webp?w=1600&q=75&auto=format)

TLDR

Peptide compounding of BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon now sits under an HHS enforcement discretion policy. A 503A pharmacy can compound them for individual patients when ten conditions are met. None is FDA-approved, the policy can be withdrawn, and public comments close November 13, 2026.

Peptide compounding for six of the most requested peptides in the market changed on October 28, 2026, and it changed through the exact door we told operators to watch. When we rebuilt our [legal peptides guide](https://www.fusehealth.com/blogs/which-peptides-are-legal-operator-guide) in August, all six read "Nobody" in the who-can-supply column. We added one caveat at the time: the government could move faster through enforcement discretion than through a formal rule. That's what HHS did.

So the column changes. It now reads something closer to "a state-licensed 503A pharmacy, against a prescription for a named patient, if ten conditions hold." And you've got until November 13 to tell HHS what you think of those conditions.

## Executive Summary

HHS says it won't take enforcement action against 503A compounders using six specific peptides, as long as all ten of its conditions are met, from a patient-specific prescription to lot-level testing and a single active ingredient. The six stay unapproved and off the 503A bulks list, state boards keep their own authority, and HHS can revisit the policy if a safety or quality problem appears. Below you'll find what's covered, what you can and can't do as an operator, how it compares with FDA approval, and how to comment before the window closes.

## What did HHS announce about peptide compounding on October 28, 2026?

HHS announced that it won't take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians that compound six named peptides under section 503A, as long as ten conditions are met. The notice was filed on October 28 and published in the Federal Register on October 30 under Docket No. HHS-OASH-2026-0496.

### Did HHS or the FDA issue the peptide policy?

The Office of the Secretary issued it, and HHS Secretary Robert F. Kennedy Jr. signed it. HHS points to significant interest in these peptides after the Pharmacy Compounding Advisory Committee met in July, and says a controlled pharmacy channel will discourage the research-use-only peptides foreign suppliers sell into the US.

> Worth knowing: The FDA reviewers at CDER who normally weigh in on bulk substances had recommended against listing all six peptides. Hall Render called the HHS-led approach unusual. Keep that split in mind when you think about how long this policy might last.

### Where can you read the official HHS and Federal Register documents?

Two documents carry the actual rules, and they're worth reading in full:

- The [Federal Register notice](https://www.federalregister.gov/d/2026-22192) announces the policy, opens the comment window and carries the Secretary's signature.
- The [HHS policy document](https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf) holds the ten conditions plus Appendix A (the peptide list) and Appendix B (identity, routes and testing). The notice says this HHS page carries the most current version.

## Are peptides legal now under the HHS peptide compounding policy?

![Are peptides legal now under the HHS peptide compounding policy - FUSE](https://cdn.sanity.io/images/yd6yvgd6/production/fb3fc5d0ad74870cb3ce2512338c7d4cc717cf7d-1920x1080.webp)

Six peptides can now be compounded by a 503A pharmacy for a named patient without federal enforcement action, provided every condition is met. They're still unapproved drugs, they're still off the 503A bulks list, and every other peptide keeps the status it had before October 28.

### What does enforcement discretion mean for peptides?

Enforcement discretion means the government is telling compounders it won't act against a specific practice for now. The notice says the policy creates no rights and binds no one, so it gives you a working route with no legal guarantee behind it.

### Is the HHS peptide policy in effect now?

The notice calls the document a draft and asks for comments by November 13, while describing how HHS intends to treat compounders in the meantime. Law firms including [Holland & Knight](https://www.hklaw.com/en/insights/publications/2026/11/hhs-issues-interim-enforcement-discretion-policy-for-compounding) describe it as an interim policy. HHS can revise it after the comment window, so check the current version on the HHS page before you change your catalog.

## Which peptides does the peptide compounding policy cover?

Appendix A names six peptides. Appendix B then narrows each one to a specific salt form and specific routes, and a product outside those limits falls outside the policy.

| Peptide  | Form      | Routes covered                                                   |
| -------- | --------- | ---------------------------------------------------------------- |
| BPC-157  | Acetate   | Subcutaneous, intramuscular, oral, topical                       |
| TB-500   | Acetate   | Subcutaneous or intramuscular injection                          |
| Epitalon | Acetate   | Subcutaneous or intramuscular injection, in intermittent courses |
| MOTS-c   | Acetate   | Subcutaneous or intramuscular injection                          |
| KPV      | Acetate   | Topical and oral                                                 |
| Semax    | Free base | Intranasal                                                       |

### Can compounding pharmacies make BPC-157 now?

Yes, within the policy's limits. A state-licensed 503A pharmacy can compound BPC-157 acetate in the four routes above for a named patient, using an ingredient from an FDA-registered manufacturer with a valid certificate of analysis. Availability still depends on each pharmacy finishing its sourcing and reporting setup, and on state law.

### Which peptides are left out of the policy?

Emideltide (DSIP), the seventh peptide the advisory committee reviewed in July, isn't on the list. Every peptide outside Appendix A keeps whatever status it had before October 28, which our [peptide ban list](https://www.fusehealth.com/blogs/fda-peptide-ban-list) tracks.

> Worth knowing: According to HHS's own Appendix B, all six peptides sat on FDA's Category 2 list of substances with significant safety concerns from September 2023 until April 22, 2026\. Coming off that list didn't change their status under 503A. This policy is what changed the practical picture.

## What does the peptide compounding policy mean for 503A pharmacies?

It gives state-licensed 503A pharmacies a conditional federal route to compound the six peptides for individual patients, with sourcing, testing, labeling and reporting duties that go further than standard 503A rules.

### What's the difference between 503A and 503B pharmacies?

A 503A pharmacy compounds against a prescription for a named patient, while a 503B outsourcing facility makes batches without patient-specific prescriptions. This policy covers 503A only, as [Arnold & Porter](https://www.arnoldporter.com/en/perspectives/advisories/2026/11/hhs-announces-draft-enforcement-discretion-policy-paving-way-for-pharmacies) noted, so a 503B facility can't fill these peptides under it. Our guide on [503A vs 503B](https://www.fusehealth.com/blogs/503a-vs-503b-which-pharmacy-for-your-program) covers how each one fits a program.

### What is the 503A bulks list?

The 503A bulks list is the list of bulk ingredients HHS approves for 503A compounding through notice-and-comment rulemaking. Section 503A lets a pharmacy use a bulk ingredient only if it has a USP or NF monograph, is a component of an FDA-approved drug, or appears on that list. None of the six peptides meets any of those three tests, which is why HHS used a separate policy.

### What are the 10 conditions for compounding peptides under the policy?

Every condition has to hold at the same time. Miss one and the pharmacy is back where it stood before October 28.

1. The peptide appears in Appendix A.
2. It matches the identity and route limits in Appendix B.
3. The bulk ingredient comes from an FDA-registered facility and carries a valid certificate of analysis (COA).
4. The original manufacturer is FDA-registered, follows current good manufacturing practice, and its facility address is printed on the COA. Any repacker or reseller in between must have validated that manufacturer and its COA.
5. The pharmacy reports what it compounds, plus serious adverse events and quality problems, to FDA's MedWatch program and to the states involved, and the patient label explains how to report issues.
6. The label reads "This is a compounded drug product. Not for resale."
7. Each product contains a single active ingredient from Appendix A.
8. Oral products come with documentation showing adequate oral bioavailability in humans.
9. The only delivery device packaged with the drug is an FDA 510(k)-cleared syringe.
10. Every other FD&C Act requirement still applies, including sanitary compounding conditions and the patient-specific prescription rule.

Most of that list lands on the pharmacy. Your job as the operator is to [pick a pharmacy](https://www.fusehealth.com/blogs/choose-right-white-label-pharmacy) that can prove each item in writing.

## Which peptide compounding conditions matter most for operators?

Four conditions shape how you build and sell a program: the prescription, the single ingredient, the ingredient source and the testing certificate.

### Do compounded peptides need a patient-specific prescription?

Yes. Condition 10 keeps 503A's rule that every compounded drug needs a valid prescription for an identified patient, so a [licensed prescriber](https://www.fusehealth.com/blogs/telehealth-prescribing-2026-what-you-can-prescribe) has to evaluate each person and make the call. On your storefront, no order ships before a prescriber approves it, and a checkout that skips clinical review doesn't fit the policy.

### Are peptide blends and stacks allowed under the policy?

No. Condition 7 limits every compounded product to one Appendix A ingredient, and HHS explains why in the policy itself: with one ingredient per product, an adverse event points to one substance. So a vial that combines BPC-157 and TB-500 sits outside the policy, even though each peptide is covered on its own.

### What counts as an approved peptide ingredient source?

The policy's word is "registered," and it's specific. The original manufacturer of the bulk peptide must be registered with FDA under section 510 and follow good manufacturing practice, and its physical address has to appear on the COA. If the pharmacy buys through a repacker or reseller, that company must have validated the manufacturer and its COA.

### What testing certificate does a compounded peptide need?

The COA has to show results that match the testing table in Appendix B, covering identity, purity, potency and contaminants like endotoxins, heavy metals and microbes. Appendix B also lists what the certificate itself must show, including the manufacturer's FDA Establishment Identifier (FEI) number, the batch number, a grade statement reading "Intended for human drug compounding" and a signature from the manufacturer's quality unit.

Ask your [pharmacy partner](https://www.fusehealth.com/blogs/white-label-pharmacy-comparison-guide-for-operators) for a sample COA for each peptide before you list anything. If it can't show you one with an FEI number on it, you've got your answer.

## Is it legal to sell peptides under the new peptide compounding policy?

![Is it legal to sell peptides under the new peptide compounding policy - FUSE](https://cdn.sanity.io/images/yd6yvgd6/production/ca1408008a4b439a5edfa52ea1b8d49d9197b3b3-1920x1080.webp)

It's legal to offer the six covered peptides through a prescription program, where a licensed prescriber evaluates each patient and a qualifying 503A pharmacy dispenses. Selling them [without a prescription](https://www.fusehealth.com/blogs/is-it-illegal-to-sell-peptides-online-and-what-to-know) stays off-limits, along with everything else in the right-hand column below.

| You can                                                               | You can't                                                                |
| --------------------------------------------------------------------- | ------------------------------------------------------------------------ |
| Offer a program where a licensed prescriber evaluates each patient    | Sell any of the six without a prescription                               |
| Route prescriptions to a 503A pharmacy that meets all ten conditions  | Rely on a 503B outsourcing facility for these peptides under this policy |
| Describe the program, the clinical review and the dispensing pharmacy | Call a compounded peptide "FDA-approved" or make treatment claims        |
| Offer each covered peptide as its own single-ingredient product       | Sell blends, or devices beyond a 510(k)-cleared syringe                  |
| File a comment on the docket before November 13                       | Resell compounded product (the label itself says "Not for resale")       |

### Are research-use-only peptides covered by the policy?

No. The policy covers state-licensed pharmacies, federal facilities and licensed physicians compounding for patients, and Holland & Knight notes that it doesn't extend to research-use-only ingredients. A website selling vials labeled "not for human consumption" gets nothing from it.

### Do state laws still apply to compounded peptides?

Yes. Federal enforcement discretion leaves state law where it was, and Holland & Knight points out that state boards of pharmacy and health departments can still restrict or prohibit these peptides. Check each state you ship into, along with your pharmacy's [state licensing](https://www.fusehealth.com/blogs/telehealth-pharmacy-licensing), before a peptide goes live there.

### Can HHS withdraw the peptide policy?

Yes. The notice keeps HHS free to revisit the policy in whole or in part if a safety signal or product quality issue appears. Build your catalog so that pulling one peptide is a settings change, and the rest of your programs keep running.

## Are compounded peptides FDA approved?

No. Compounded drugs aren't FDA-approved, and the HHS policy says so directly: FDA doesn't review their safety, effectiveness or quality before they're marketed. Here's how the two compare.

| Question                                           | FDA-approved drug                            | Covered by the HHS policy                               |
| -------------------------------------------------- | -------------------------------------------- | ------------------------------------------------------- |
| FDA reviewed safety and effectiveness before sale? | Yes                                          | No                                                      |
| Who makes it?                                      | A manufacturer under an approved application | A 503A pharmacy, one patient at a time                  |
| How long does the status last?                     | Until FDA withdraws approval                 | Until a final bulks-list rule, or until HHS revisits it |
| Can your marketing claim it treats a condition?    | Only for approved uses                       | No                                                      |

### How is enforcement discretion different from FDA approval?

[FDA approval](https://www.fusehealth.com/blogs/what-peptides-are-fda-approved-2026-list), a spot on the 503A bulks list and enforcement discretion are three separate things, and these six only have the third. A bulks-list spot takes notice-and-comment rulemaking, while enforcement discretion is the government saying it won't act for now.

### How should you market a compounded peptide program?

Advertise the program, describe the clinician's role, and say that medication, if prescribed, is compounded by a licensed pharmacy. Keep peptide names away from disease or outcome claims. Ad platforms and [LegitScript certification](https://www.fusehealth.com/blogs/legitscript-certification-telehealth-cost-timeline-process) run on their own rules, and this policy doesn't touch them.

## How do you comment on the HHS peptide compounding policy before November 13?

You submit a comment on Regulations.gov under Docket No. HHS-OASH-2026-0496\. HHS gave the public two weeks from publication, so comments close November 13, 2026.

### How to submit a comment on Regulations.gov

1. Open the [comment docket](https://www.regulations.gov/docket/HHS-OASH-2026-0496) for Docket No. HHS-OASH-2026-0496 on Regulations.gov.
2. Select the notice titled "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances," then select Comment.
3. Type your comment or attach it as a file, fill in the submitter details, and submit.
4. Save the tracking number you get back, and check the exact closing time shown on the docket page.

### What should a useful comment include?

- Say who you are and where you sit (operator, prescriber group, pharmacy partner).
- Name the specific condition you're addressing by number.
- Share evidence you actually hold, such as sourcing problems, COA gaps or reporting experience.
- Propose the wording you want. For example, HHS hasn't defined what documentation proves "adequate oral bioavailability," a gap [McDermott](https://www.mcdermottlaw.com/insights/peptides-first-paperwork-later-hhs-clears-six-for-compounding-ahead-of-bulks-list-rulemaking/) flagged, so asking for a defined standard is a concrete, answerable request.

### What should you leave out of a public comment?

Comments on Regulations.gov are generally posted publicly. Leave out patient information and anything you'd treat as confidential, and have counsel read your draft if it describes your own compliance setup.

## How does FUSE Health run peptide compounding programs inside the policy?

FUSE Health is the [infrastructure layer](https://www.fusehealth.com/peptide-telehealth) behind your brand. You own the storefront, the pricing and the customer, and the clinical and pharmacy steps run behind it.

![How does FUSE Health run peptide compounding programs inside the policy - FUSE](https://cdn.sanity.io/images/yd6yvgd6/production/2e8d74cefd4abd33e9d87034cbe36eafb2026a5c-1920x1080.webp)

### How does a compliant peptide order move from storefront to pharmacy?

Each order follows a [fixed sequence](https://www.fusehealth.com/how-this-works):

1. Your customer completes a structured intake on your branded storefront.
2. An independent licensed clinician in the customer's state reviews it and approves, adjusts or declines.
3. The order is checked against the customer's state before approval.
4. Approved prescriptions route to a pharmacy partner that compounds and ships directly to the named patient.

### Where do peptide programs usually break?

Programs usually break in predictable places: a blend left in the catalog, one pharmacy carrying every order with no backup, or a product page that puts a peptide name next to a result. All three are cheaper to fix before launch than after the first rejected order, so ask any platform you're evaluating, including us, to show you how a peptide comes out of live checkout in one step.

## Build your peptide compounding program for a policy that can move

Six peptides now have a federal route to a patient that runs through a prescriber, a 503A pharmacy and ten conditions, and that route is provisional. Read the notice and the policy yourself, get your pharmacy to prove each condition on paper, and file a comment before November 13 if any condition would break your model. Then set up your catalog so a change in Washington costs you one configuration update, which is exactly what FUSE Health is built for. Book a consultation and get your program mapped before you list a single covered peptide.

> Disclaimer

> This article is general information for healthcare business operators about a federal enforcement policy. It isn't legal or medical advice; it doesn't describe the use or effects of any substance, and it doesn't recommend any treatment. Independent licensed clinicians make all prescribing decisions on programs powered by FUSE. Confirm every point with your own counsel and your pharmacy partner before you change what you offer.

## References

1. [U.S. Department of Health and Human Services, Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendices A and B, October 28, 2026.](https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf)
2. [Federal Register, Doc. 2026-22192, Docket No. HHS-OASH-2026-0496, filed October 28, 2026, published October 30, 2026.](https://www.federalregister.gov/d/2026-22192)
3. [Regulations.gov, Docket HHS-OASH-2026-0496.](https://www.regulations.gov/docket/HHS-OASH-2026-0496)
4. [Holland & Knight, HHS Issues Interim Enforcement Discretion Policy for Compounding of 6 Peptides, November 2026.](https://www.hklaw.com/en/insights/publications/2026/11/hhs-issues-interim-enforcement-discretion-policy-for-compounding)
5. [McDermott Will & Schulte, Peptides First, Paperwork Later, November 2, 2026.](https://www.mcdermottlaw.com/insights/peptides-first-paperwork-later-hhs-clears-six-for-compounding-ahead-of-bulks-list-rulemaking/)
6. [Arnold & Porter, HHS Announces Draft Enforcement Discretion Policy, November 2, 2026.](https://www.arnoldporter.com/en/perspectives/advisories/2026/11/hhs-announces-draft-enforcement-discretion-policy-paving-way-for-pharmacies)
7. [Hall Render, HHS, Not FDA, Takes the Lead on Peptide Compounding, November 4, 2026.](https://hallrender.com/2026/11/04/hhs-not-fda-takes-the-lead-on-peptide-compounding/)
8. [AJMC, 5 Things to Know About HHS's Interim Peptide Compounding Policy, October 29, 2026.](https://www.ajmc.com/view/5-things-to-know-about-hhs-s-interim-peptide-compounding-policy)

![Daniel Meursing](https://cdn.sanity.io/images/yd6yvgd6/production/ef49a0c35413d503a60b98969aa02be40a9dab28-1200x632.jpg)

Daniel Meursing

CEO

Daniel is a two-time founder who has scaled service businesses across major U.S. markets. A Y Combinator competition winner, he focuses on removing operational and regulatory barriers so operators can build and scale modern healthcare businesses.

Background

Startup Operations & Service Systems

Experience

2x Founder, Multi-Market U.S. Scaling

Qualifications

Healthtech Market Expertise & Operational Scaling

Key Achievement

Scaled Premier Staff & Eventstaff across major U.S. markets

## Frequently Asked Questions

### Is Semax legal to compound under the HHS peptide policy?

Only in one form. The policy covers Semax free base for intranasal use, compounded from an ingredient with a qualifying certificate of analysis. Other forms and routes fall outside it, and state law can still restrict it.

### Can telehealth providers prescribe peptides covered by the policy?

The policy doesn't mention telehealth. It requires a valid prescription for an identified patient, and state rules decide whether that prescription can come from a telehealth visit in the patient's state, so check prescribing rules state by state.

### Can a med spa or wellness brand sell compounded peptides under this policy?

Yes, through the prescription route. A licensed prescriber has to evaluate each customer and a qualifying 503A pharmacy has to dispense. Our guide on how med spas sell peptides walks through that setup, and the peptide business guide covers the wider model.

### How long will the HHS peptide compounding policy last?

For each peptide, until a final rule decides whether it goes on the 503A bulks list, or until HHS revisits the policy because of a safety or quality issue. No rulemaking timeline has been published.

### Will more peptides be added to the peptide compounding policy?

Not automatically. The advisory committee was scheduled to review five more peptides in February 2027, AJMC reports. Any new peptide would need HHS to amend Appendix A or FDA to finish rulemaking.

Ready to act on this?

- [Launch your own brandSee how brands go live on FUSE.](https://www.fusehealth.com/brands)
- [Join as a providerSee how clinicians work with FUSE brands.](https://www.fusehealth.com/provider)
- [See pricingEvery plan and fee, published.](https://www.fusehealth.com/pricing)

 In this guide

- [Frequently Asked Questions](#faq)

Launch faster

Go live with a compliant, branded peptide program — prescribing, pharmacy, and providers included.

Share

[](https://x.com/intent/post?url=https%3A%2F%2Fwww.fusehealth.com%2Fblogs%2Fpeptide-compounding-hhs-policy-explained&text=Peptide%20Compounding%20Under%20the%20New%20HHS%20Policy%3A%20What%20Healthcare%20Operators%20Can%20and%20Cannot%20Do)[](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.fusehealth.com%2Fblogs%2Fpeptide-compounding-hhs-policy-explained)

## Recent Posts

[The FDA Peptide Ban List: What Was Removed, and What You Can Still PrescribeFUSE Health · 10 min read](https://www.fusehealth.com/blogs/fda-peptide-ban-list)[Which Peptides Are Legal? What Your Business Can Offer, Dispense and Advertise in 2026FUSE Health · 24 min read](https://www.fusehealth.com/blogs/which-peptides-are-legal-operator-guide)[What Peptides Are FDA Approved? The Complete 2026 ListFUSE Health · 11 min read](https://www.fusehealth.com/blogs/what-peptides-are-fda-approved-2026-list)[White Label Peptides: The Current FDA Category 2 ListFUSE Health · 9 min read](https://www.fusehealth.com/blogs/white-label-peptides-fda-category-2-list)

## Building a Peptide Brand?

See how FUSE infrastructure can help you launch and scale a compliant program faster.
